David Reardon, M.D., clinical director at the Center for Neuro-oncology at the Dana-Farber Cancer Institute, breaks down a common misconception that many people have about glioblastoma (GBM).
David Reardon, M.D., clinical director at the Center for Neuro-oncology at the Dana-Farber Cancer Institute, breaks down a common misconception that many people have about glioblastoma (GBM).
When people hear about a GBM diagnosis, their first thoughts might be that there is little to no hope in treating the disease. However, recent scientific advances continue to improve outcomes for people with GBM. For example, a SurVaxM, an agent that harnesses the body’s immune system to fight the cancer, has shown promising results in trials and was granted an Orphan Drug Status by the Food and Drug Administration (FDA) in early August. Other immunotherapy agents are also in the pipeline.
